Skip to main content
Catherine Bollard, MD, Pediatric Hematology & Oncology, Washington, DC

CatherineBollardMD

Pediatric Hematology & Oncology Washington, DC

Professor, Pediatrics and Microbiology, Immunology and Tropical Medicine The George Washington University Director- Program for Cell Enhancement and Technologies for Immunotherapy Children's National Health System and Chief, Division of Allergy and Immunology CNHS

Dr. Bollard is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Bollard's full profile

Already have an account?

  • Office

    111 Michigan Ave Nw
    Washington, DC 20010
    Phone+1 202-476-4776
    Fax+1 832-825-4247

Education & Training

  • University of Otago School of Medicine
    University of Otago School of MedicineMD, Immunology, 2000 - 2005
  • Registrar - Hematology
    Registrar - HematologyFRCPA, Hematology, 1997 - 2002
  • Registrar- Pediatrics
    Registrar- PediatricsFRACP, Pediatrics, 1995 - 2002
  • University of Otago School of Medicine
    University of Otago School of MedicineClass of 1991

Certifications & Licensure

  • DC State Medical License
    DC State Medical License 2013 - 2025
  • TX State Medical License
    TX State Medical License 2004 - 2014
  • Royal Australian College of PhysicansPediatrics and Child Health Division
  • Royal College of Pathologists of AustraliaHematology and Immunology

Awards, Honors, & Recognition

  • Induction into the Henry Kunkel Society 2014
  • Basi Science Award European Group for Blood and Marrow Transplantation (EBMT), 2011
  • Elected Member The American Society for Clinical Investigation, 2010
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Management Guidelines for Paediatric Patients Receiving Chimeric Antigen Receptor T Cell Therapy  
    Kris M Mahadeo, Julie C Fitzgerald, Marie E Steiner, Partow Kebriaei, Katayoun Rezvani, Ira M Cheifetz, John M Slopis, Paul L Martin, Sattva S Neelapu, Agne Tarasevici..., Nature
  • EBV/LMP-specific T Cells Maintain Remissions of T and B Cell EBV Lymphomas After Allogeneic Bone Marrow Transplantation  
    Stephen Gottschalk, Rayne Rouce, Catherine M Bollard, Malcolm K Brenner, Helen E Heslop, Blood
  • Reduced Intensity Conditioning for Hematopoietic Cell Transplant for HLH and Primary Immune Deficiencies: BMT CTN 1204  
    Shalini Shenoy, K Scott Baker, Elizabeth O Stenger, Mary Eapen, Carl Allen, Lauri Burroughs, Philip Roehrs, Catherine M Bollard, Rabi Hanna, Jeffrey R Andolina, James ..., Blood
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Abstracts/Posters

  • Identifying Novel Immunodominant Epitopes within Human Parainfluenza Virus-3 Matrix Protein
    Catherine M. Bollard, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Blocking MAPK Activation and Immune Checkpoints Reverse Immune Dysfunction and Reduce Disease in a Mouse Model of LCH
    Catherine M. Bollard, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Ultra low-dose il-2 mediated expansion of regulatory T cells as GVHD prophylaxis for recipients of allogeneic hematopoietic stem cells blood transplantation.
    Catherine Bollard 1,*,Alana Kennedy-Nasser 2,A. John Barrett 3,Sawa Ito 3,Eric Yvon 4,Robert Krance 2,Kathryn Leung 2,Helen E. Heslop 2,Malcolm K. Brenner2, Poster Presentation, EBMT; Bone Marrow Transplant, Milan, Italy, 1/31/2014
  • Join now to see all

Lectures

  • Optimizing Clinical Outcomes in Blood Cancers Through Groundbreaking Translational Research 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Meet the Blood Editors 
    60th American Society of Hematology Annual Meeting - 12/3/2018
  • Meet the Blood Editors 
    60th American Society of Hematology Annual Meeting - 12/1/2018
  • Join now to see all

Other

Press Mentions

  • Cutting Edge Advancements in Regenerative Medicine Takes Centerstage at 2nd Annual ADSCC Bone Marrow Transplant & Cellular Therapy Congress 2024
    Cutting Edge Advancements in Regenerative Medicine Takes Centerstage at 2nd Annual ADSCC Bone Marrow Transplant & Cellular Therapy Congress 2024October 28th, 2024
  • Breaking Free of Illness: Experts Explore Solutions for Chronic Pediatric Disorders
    Breaking Free of Illness: Experts Explore Solutions for Chronic Pediatric DisordersSeptember 23rd, 2024
  • Access4Kids: A New Model to Pay for Pediatric Cell and Gene Therapies
    Access4Kids: A New Model to Pay for Pediatric Cell and Gene TherapiesAugust 22nd, 2024
  • Join now to see all

Grant Support

  • Anti-Viral And Antileukemic T-Cell Therapy As Prophylaxis After HSCTNational Heart, Lung, And Blood Institute2011
  • Clinical Trial: The Administration Of Neomycin Resistance Gene Marked EBV SpeciNational Center For Research Resources2011
  • Clinical Trial: Neomycin Resistance LMP2A Specific Cytotoxic T-Lymphocytes ForNational Center For Research Resources2011
  • Adoptive Transfer Of Cord Blood T Cells To Prevent And Treat CMV And AdenovirusNational Center For Research Resources2011
  • Improving Cord Blood TransplantationNational Cancer Institute2011
  • Enhancing Treg Immune Reconstitution After Stem Cell TransplantNational Cancer Institute2011
  • Administration Of Tgf-B Resistant Lmp2a-Specific Cytotoxic T-Lymphocytes To PNational Center For Research Resources2010–2011
  • Clinical Trial: Virus Specific Cytotoxic T-Lymphocytes For The Prophylaxis Of CMNational Center For Research Resources2008–2011
  • Clinical Trial: Neomycin Resistance LMP2A Specific Cytotoxic T-Lymphocytes For ENational Center For Research Resources2008–2010
  • Clinical Trial: Administration Of Virus-Specific Cytotoxic T-Lymphocytes For TheNational Center For Research Resources2008–2010
  • Clinical Trial: Administration Of Neomycin Resistance Gene Marked EBV Specific CNational Center For Research Resources2008–2009
  • Clinical Trial: Administration Of Lmp2a-Specific Cytotoxic T-Lymphocytes FollowNational Center For Research Resources2008
  • Administration Of Virus-Specific Cytotoxic T-Lymphocytes For The ProphylaxisNational Center For Research Resources2007
  • Administration Of Lmp2a-Specific Cytotoxic T-Lymphocytes Following CD45 AntiNational Center For Research Resources2006–2007
  • Virus Specific Cytotoxic T-Lymphocytes For The Prophylaxis Of CMVNational Center For Research Resources2005–2007
  • Neomycin Resistance LMP2A Specific Cytotoxic T-Lymphocytes For EBV Pos LymphomaNational Center For Research Resources2005–2007
  • Administration Of Lmp2a-Specific Cytotoxic T-Lymphocytes Following CD45National Center For Research Resources2005
  • Neomycin Resistance LMP2A Specific Cytotoxic T-Lymphocytes For EBV Pos. LymphomaNational Center For Research Resources2004